

Claim 143, line 2, delete "essentially".

Claim 144, line 3, delete "essentially".

Claim 145, line 2, delete "essentially".

Claim 153, line 2, delete "essentially".

Claim 155, line 1, delete "of using the composition";

Line 1, replace "1 to treat" with ---157, wherein said---

Line 2, replace "in need thereof," with ---are---

IN THE SPECIFICATION:

Page 1, line 10, before, "continuation-in-part", insert ---divisional application of
A8 08/789,734, which is a---

Page 48, after line 27, insert ---and testosterone propionate; sulfonamides;
A9 sympathomimetic agents; vaccines; vitamins and---

Page 49, after line 27, insert ---agents; including anti-kaposi's sarcoma; anti-
A8 convulsants such as mephenytoin;---

Page 50, after line 27, insert ---seminis; Mycoplasma bovigenitalium; Aspergillus
A9 fumigatus, Absidia ramosa;---

Page 51, after line 27, insert ---polypeptide is between 1,000 - 250,000 daltons.---
A10

Page 52, after line 27, insert ---6. *A K R H H G Y K R K F H---
A10

Page 53, after line 27, insert ---of uncapped and end-capped forms, in ratios
A12 ranging from 48/52 to 52/48.---

Page 54, after line 27, insert ---maintain the solution pH around the microcapsules
A12 and preserve the biological---

Page 55, after line 27, insert ~~---~~emulsifying to provide an inner water-in-oil

A13 (w/o)emulsion; stabilizing the---

Page 57, after line 27, insert ~~---~~bacteria selected from the group consisting---

A15
A16 Page 59, after line 27, insert ~~---~~22 (Gly-Asn-Ala-Leu-Pro Ser-Ala-Val),---

Page 60, after line 27, insert ~~---~~bacter spp., Foavobacterium, Pseudomonas,

A17 Legionella, Brucella, ---.

Page 66, after line 27, insert ~~---~~Anaerobic gram-Positive Nonsporeforming Bacilli

A18 and Cocci, yersinia,---

Page 68, after line 27, insert ~~---~~by a bacteria selected from the group consisting

A19 essentially of Salmonella---

Page 69, after line 27, insert ---which contains antibodies directed against the

A20 hepatitis B virus.---

Page 71, after line 27, insert ~~---~~within the range of 48/52 to 52/48 based on the

A21 weight of said polymeric---

Page 73, after line 27, insert ~~---~~II diabetes; visceral leishmaniasis; malaria;

A22 periodontal or gum disease; cardiac---

Page 74, after line 27, insert ~~---~~psoriasis; basal cell carcinoma; benign prostatic

A23 hypertrophy; blood substitute;---

Page 75, after line 27, insert ~~---~~osteoporosis; drug addiction; shock; ovarian

A24 cancer; Amebiasis; Babesiasis;---

Page 76, line 9 replace "inventionpresents" with ~~---~~invention presents---

Page 169, top of page, delete "156".

Page 171, top of page, delete "158";

Page 228, lines 13, 27 and 44, replace "Table 14" with --Table 16--.

Page 229, lines 8, 23 and 38, replace "Table 14" with --Table 16--.

Page 230, line 1, replace "Table 14" with --Table 16--.

Page 280, line 1, after "Table" replace "15" with ---16---.

Page numbering:

Page 1-88, before line 1, delete page nos. "1-88";

bottom of the pages, insert page nos. --- 1-88 ---, respectively.

Page 89, before line 1, delete page no. "89";

between line 6 and 7, insert page no. ---89--- and do a page break;

before "RESULTS OF EXAMPLES 1 THROUGH 7", insert "Tables 1-8
respectively from old pages 272-279, respectively;

bottom of the page, insert page no. ---98---.

Pages 90-230, before line 1, delete page nos. "90-230";

bottom of the pages, insert page nos. --- 99-238 ---, respectively.

Page 231, before line 1, delete page no. "231";

bottom of the page, insert page no. ----239---;

after page 231, insert --- Table 16 --- from old pages 280-283 and
renumber at the bottom of the pages as new page nos. --- 240-243 ---, respectively.

Pages 232-271, before line 1, delete page nos. "232-271";

bottom of the pages; insert page nos. ---- 244-283 ---, respectively.